Safety and Tolerability of PNT001 in Patients With Acute Traumatic Brain Injury (TBI)

NCT ID: NCT04677829

Last Updated: 2022-06-29

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 1 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-03-29
• Study Completion Date: 2021-04-12

Brief Summary

This is a Phase 1, multi-center, randomized, double-blind, placebo-controlled, multiple-ascending- dose trial to evaluate the safety, tolerability, immunogenicity, and pharmacokinetics of intravenous PNT001 in hospitalized patients with traumatic brain injury.

Detailed Description

The Phase 1 study is a double-blind, multiple ascending dose trial evaluating a total of 64 patients across two dose cohort groups. Each cohort will include 32 patients (24 active; 8 placebo) who will be randomized to receive three doses of either PNT001 or placebo. Doses studied will be 1000mg and 4000mg.

Patients admitted to the trauma center who meet entrance criteria will receive their first dose of study drug within 24 hours of documented TBI. They will remain in the facility for at least 24 hours after initial dose. Baseline biomarker collection and cognitive assessments will be completed. Study medication will be administered as an IV infusion over 30 minutes (for 1000mg cohort) or 60 minutes (for 4000mg cohort) followed by collection of safety, tolerability, pharmacokinetic, biomarker, imaging, and cognitive data over 12 weeks. Subsequent dosing visits will be at Days 28 and 56. All visits after initial discharge will be on an outpatient basis.

Conditions

Traumatic Brain Injury

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

PNT001 1000mg

PNT001 diluted in 5% dextrose for infusion

Group Type: EXPERIMENTAL

PNT001

Intervention Type: BIOLOGICAL

30 minute infusion for PNT001 1000mg; 60 minute infusion for PNT001 4000mg

PNT001 4000mg

PNT001 diluted in 5% dextrose for infusion

Group Type: EXPERIMENTAL

%5 dextrose for infusion

Intervention Type: BIOLOGICAL

30 min placebo infusion for 1000mg; 60 minute placebo infusion for 4000mg

Placebo

5% dextrose for infusion

Group Type: PLACEBO_COMPARATOR

PNT001

Intervention Type: BIOLOGICAL

30 minute infusion for PNT001 1000mg; 60 minute infusion for PNT001 4000mg

%5 dextrose for infusion

Intervention Type: BIOLOGICAL

30 min placebo infusion for 1000mg; 60 minute placebo infusion for 4000mg

Interventions

PNT001

30 minute infusion for PNT001 1000mg; 60 minute infusion for PNT001 4000mg

Intervention Type: BIOLOGICAL

%5 dextrose for infusion

30 min placebo infusion for 1000mg; 60 minute placebo infusion for 4000mg

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Hospitalization due to documented evidence of TBI with Glasgow Coma Scale (GCS) Score 9-12 or GCS score of 13-15 with radiographic evidence of trauma.

2. Duration from documented time of TBI event to time of start of initial dose of study drug will not exceed 24 hours.

3. Signed informed consent by patient, or where applicable, patient's legally authorized representative.

4. Male and females, 18- 65 years of age at time of screening (State's legal age of majority is minimum age if higher than 18).

5. Female patients must meet protocol defined criteria for 1) non-childbearing potential, 2) post menopausal or 3) must have a negative pregnancy test and agree to contraception as outlined in the protocol.

6. Male must agree to use acceptable contraception and refrain from sperm donation during the entire study and for 200 days after dosing has been completed.

7. Has not participated in a clinical drug trial within 3 months of study start.

8. Body Mass Index (BMI) of 18.5-35.0 kg/m2 and for the 4000mg dose group only, weight greater than or equal to 44.8 kg.

9. Vision, hearing, speech, motor function, and comprehension sufficient for compliance with all testing procedures and assessments.

Exclusion Criteria

1. TBI that does not require hospitalization.

2. TBI outside 24-hour window.

3. GCS < 9 within 2 hours of dosing.

4. History of TBI in past 12 months that resulted in patient seeking medical attention.

5. Evidence of penetrating head trauma or depressed skull fracture.

6. Clinical or radiographic evidence of mass effect, midline shift, or intracranial hypertension, requiring craniotomy/craniectomy.

7. Evidence of symptomatic cervical, thoracic, lumbar spine injury e.g. paresis, radiculopathy, that can be localized to the injury.

8. Systemic traumatic injury that would preclude participation in study or is expected to result in long-term disability.

9. Any other acute or chronic medical illness that in the judgement of the study physician results in functional impairment or impairs neuropsychiatric function.

10. Any acute intoxication that in the judgement of the study physician results in significant functional impairment or impairs neuropsychiatric function.

11. Any history of cancer within 5 years of enrollment with the exception of resected skin basal cell carcinoma.

12. Any major surgery requiring general anesthesia within 4 weeks of study drug administration.

13. Donation of blood or serum ≥500 mL to a blood bank or in a clinical study (except screening visit) within 3 months of study drug administration.

14. Known recent (within 6 months of study drug administration) drug or alcohol abuse as defined in DSM V, Diagnostic Criteria for Drug and Alcohol Abuse.

15. Evidence of any clinically significant neurological or psychiatric disorder that could interfere with study assessments as determined by investigator and sponsor.

16. Patient has history or currently has schizophrenia, schizoaffective disorder or bipolar disorder, untreated major depression (DSM-V or ICD-10 criteria).

17. Significant illness within the prior 30 days.

18. Abnormalities in creatinine, hepatic transaminases, or QT that would preclude entry into the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

United States Department of Defense

FED

Sponsor Role: collaborator

Pinteon Therapeutics, Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Larry Altstiel, MD, PhD

Role: STUDY_DIRECTOR

Pinteon Therapeutics

Locations

Penn Presbyterian Medical Center

Philadelphia, Pennsylvania, United States

Countries

United States

Other Identifiers

PNT001-002

Identifier Type: -

Identifier Source: org_study_id